Q2 2025 EPS Estimates for Prestige Consumer Healthcare Inc. (NYSE:PBH) Lowered by Analyst

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities researchers at Zacks Research dropped their Q2 2025 EPS estimates for Prestige Consumer Healthcare in a research note issued on Thursday, August 29th. Zacks Research analyst R. Department now forecasts that the company will earn $1.09 per share for the quarter, down from their previous estimate of $1.12. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.42 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2025 earnings at $1.20 EPS, Q2 2026 earnings at $1.18 EPS, Q4 2026 earnings at $1.23 EPS, Q1 2027 earnings at $1.20 EPS and FY2027 earnings at $4.92 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The business had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same period last year, the business posted $1.06 EPS. The company’s revenue was down 4.4% compared to the same quarter last year.

PBH has been the topic of a number of other research reports. DA Davidson raised their price target on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Prestige Consumer Healthcare in a research report on Tuesday, May 21st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and an average price target of $98.75.

Prestige Consumer Healthcare Price Performance

NYSE PBH opened at $74.11 on Monday. Prestige Consumer Healthcare has a one year low of $56.34 and a one year high of $75.31. The stock has a 50-day moving average of $69.93 and a 200 day moving average of $69.33. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23. The company has a market capitalization of $3.68 billion, a price-to-earnings ratio of 17.77, a PEG ratio of 2.11 and a beta of 0.49.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Institutional investors have recently made changes to their positions in the business. Covestor Ltd increased its holdings in Prestige Consumer Healthcare by 21.6% during the first quarter. Covestor Ltd now owns 834 shares of the company’s stock valued at $61,000 after buying an additional 148 shares during the last quarter. Evergreen Capital Management LLC increased its stake in shares of Prestige Consumer Healthcare by 5.4% in the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock worth $216,000 after purchasing an additional 160 shares in the last quarter. Miller Howard Investments Inc. NY raised its holdings in Prestige Consumer Healthcare by 2.2% in the 2nd quarter. Miller Howard Investments Inc. NY now owns 7,762 shares of the company’s stock worth $534,000 after purchasing an additional 165 shares during the period. EverSource Wealth Advisors LLC lifted its position in Prestige Consumer Healthcare by 80.6% during the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares in the last quarter. Finally, Parallel Advisors LLC grew its holdings in Prestige Consumer Healthcare by 42.5% during the fourth quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock valued at $44,000 after purchasing an additional 213 shares during the period. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.